CLDN4 and non-small cell lung carcinoma: Reports assessing Claudin-4 in non-small cell lung cancer revealed mild positive results in 469 of 502 (93%) carcinomas and five of 463 (1.0%) epithelioid/biphasic mesotheliomas (sensitivity 93%, specificity 98.9%) (12).